Takeda Pharmaceutical (NYSE:TAK) Upgraded to "Outperform" at Sanford C. Bernstein

Key Points

• Sanford C. Bernstein upgraded Takeda Pharmaceutical from "market perform" to "outperform" in a research note issued Wednesday.
• Analyst coverage is mixed but tilted positive: two analysts rate the stock Buy and two rate it Hold, giving Takeda a consensus rating of "Moderate Buy."
• Takahda's recent quarter missed expectations with $0.48 EPS vs. $0.55 forecast and $7.60B revenue vs. $7.81B consensus, while shares trade near a 12-month high ($18.74 midday, 12‑month range $12.99–$18.90) and the company set FY2025 guidance at 3.160 EPS.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) was upgraded by stock analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating in a research note issued to investors on Wednesday, MarketBeat reports.

A number of other equities research analysts have also issued reports on TAK. Morgan Stanley began coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an "overweight" rating on the stock. Wall Street Zen lowered shares of Takeda Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 21st. Zacks Research upgraded shares of Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy".

Takeda Pharmaceutical Price Performance

Shares of TAK stock traded up $0.45 during midday trading on Wednesday, reaching $18.74. 421,682 shares of the company were exchanged, compared to its average volume of 2,996,342. Takeda Pharmaceutical has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a market cap of $59.62 billion, a P/E ratio of 78.11 and a beta of -0.01. The company's 50 day moving average price is $18.13 and its two-hundred day moving average price is $15.93. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Friday, January 30th. The company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.55 by ($0.07). Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%.The business had revenue of $7.60 billion during the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. On average, sell-side analysts expect that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

Several large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its holdings in shares of Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company's stock worth $6,558,000 after buying an additional 43,706 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Takeda Pharmaceutical by 43.6% during the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company's stock worth $2,911,000 after buying an additional 59,442 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock worth $79,120,000 after buying an additional 692,404 shares during the period. Focus Partners Wealth boosted its holdings in shares of Takeda Pharmaceutical by 4.1% during the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company's stock worth $1,230,000 after buying an additional 3,239 shares during the period. Finally, Sivia Capital Partners LLC bought a new stake in shares of Takeda Pharmaceutical during the 2nd quarter worth $351,000. 9.17% of the stock is owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.